Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate forDepression?
Current Molecular Pharmacology August 9, 2023 MIng Tatt Lee, Yu‐Cheng Ho 2 citations
Ketamine and its metabolite (2R,6R)-hydroxynorketamine show rapid antidepressant effects in models of major depressive disorder. The review discusses how these compounds work differently from traditional antidepressants, potentially offering faster relief for treatment-resistant depression. The FDA-approved nasal spray Spravato (esketamine) is highlighted as a clinical application. The text suggests that understanding the mechanisms of these compounds could lead to better treatments for major depressive disorder.